Twist Bioscience Corp (TWST) Q4 2025 10-Q Quarterly Report
Filed: Feb 2, 2026Period ending Dec 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Twist Bioscience Corp (TWST) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 2, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Twist Bioscience Corp Q4 2025 10-Q Analysis
Risk Factors
- • No material changes in risk factors from 10-K; risks primarily forward-looking statement disclaimers
- • Regulatory risk: potential liability from undisclosed future acquisitions, mergers, or joint ventures
Twist Bioscience Corp Q4 2025 Quarterly FinancialsXBRL
Revenue
$104M
▲ +16.9% YoY
Net Income
-$31M
▲ +3.4% YoY
Operating Margin
-31.7%
▲ +733bp YoY
Net Margin
-29.4%
▲ +619bp YoY
ROE
-6.7%
▲ +24bp YoY
Total Assets
$638M
▲ +4.8% YoY
EPS (Diluted)
$-0.50
▲ +5.7% YoY
Operating Cash Flow
-$25M
▼ -15.8% YoY
Source: XBRL data from Twist Bioscience Corp Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Twist Bioscience Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.